QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 contextlogic-q3-eps-007-misses-004-estimate

ContextLogic (OTC:LOGC) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.04) b...

 retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

 contextlogic-q2-eps-023-misses-004-estimate

ContextLogic (NASDAQ:LOGC) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.04...

 contextlogic-q1-eps-027-misses-008-estimate

ContextLogic (NASDAQ:LOGC) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.08...

 contextlogic-and-bc-partners-forge-150-million-strategic-partnership-for-growth

BC Partners invests $150M in ContextLogic, providing access to $300M in capital. New board members to maximize shareholder valu...

 contextlogic-q3-2024-gaap-eps-004-misses-001-estimate

ContextLogic (NASDAQ:LOGC) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01...

 contextlogic-q2-2024-adj-eps-050-misses-006-estimate-sales-700m-beat-174m-estimate

ContextLogic (NASDAQ:LOGC) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.06...

 logicbio-therapeutics-q3-eps-018-up-from-031-yoy

LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losse...

 logicbio-therapeutics-says-on-oct-14-co-received-compliance-letter-from-nasdaq-notifying-that-cos-bid-price-deficiency-had-been-cured

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION